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nrico.gerace@antidAbstract A fast screening protocol was developed for the simultaneous determination of nine anti-
estrogenic agents (aminoglutethimide, anastrozole, clomiphene, drostanolone, formestane, letrozole,
mesterolone, tamoxifen, testolactone) plus ﬁve of their metabolites in human urine. After an enzymatic
hydrolysis, these compounds can be extracted simultaneously from urine with a simple liquid–liquid
extraction at alkaline conditions. The analytes were subsequently analyzed by fast-gas chromatography/
mass spectrometry (fast-GC/MS) after derivatization. The use of a short column, high-ﬂow carrier gas
velocity and fast temperature ramping produced an efﬁcient separation of all analytes in about 4 min,
allowing a processing rate of 10 samples/h. The present analytical method was validated according to UNI
EN ISO/IEC 17025 guidelines for qualitative methods. The range of investigated parameters included the
limit of detection, selectivity, linearity, repeatability, robustness and extraction efﬁciency. High MS-
sampling rate, using a benchtop quadrupole mass analyzer, resulted in accurate peak shape deﬁnition
under both scan and selected ion monitoring modes, and high sensitivity in the latter mode. Therefore, the
performances of the method are comparable to the ones obtainable from traditional GC/MS analysis. The
method was successfully tested on real samples arising from clinical treatments of hospitalized patients and
could proﬁtably be used for clinical studies on anti-estrogenic drug administration.
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E. Gerace et al.21. Introduction
According to their pharmacological properties, substances with
anti-estrogenic activity can be classiﬁed in aromatase inhibitors
(aminoglutethimide, anastrozole, exemestane, formestane, letro-
zole, testolactone), selective estrogen receptor modulators
(raloxifene, tamoxifen, toremifene), substances with secondary
anti-estrogenic activity (drostanolone, mesterolone) and other
anti-estrogenic substances (clomiphene, cyclofenil, fulvestrant).
The therapeutic prescription for aromatase inhibitors is the
treatment of metastatic breast cancer in post-menopausal women,
because the inhibition of estrogens biosynthesis is supposed to
prevent the growth of tumor tissue [1–3]. Selective estrogen
receptor modulators (SERMs) exhibit a mixed pharmacologic
proﬁle, characterized by estrogen agonist activity in some tissues
and estrogen antagonist activity in others. SERMs have many
potential pharmacological applications, and are currently pre-
scribed for women with breast cancer (tamoxifen, toremifene) or
at risk for breast cancer (tamoxifen), and lastly for post-meno-
pausal women with a risk of osteoporosis (raloxifene) [4,5].
Clomiphene and cyclofenil have stimulating effects on the secre-
tion of hypophysical gonadotropic hormones and are mainly used
in the treatment of infertility [6,7].
Drostanolone and mesterolone are mainly considered as
anabolic agents, but they also show some secondary anti-
estrogenic effects [8].
Moreover, anti-estrogenic agents can be illicitly used in
sport as they are able to treat and prevent the side effects
produced from anabolic androgenic steroids misuse [9].
Accordingly, the use of anti-estrogenic agents is prohibited
by World Anti-Doping Agency (WADA) regulations for both
male and female athletes in- and out-competitions [10].
Different conventional approaches, carried out on biologi-
cal ﬂuids (blood and urine), were reported for the detection of
anti-estrogens, including immuno-analytical techniques [11],
and chromatographic methods [12,13]. Since the consumption
of these compounds by the athletes is prohibited in sport
events, several screening procedures were developed for the
detection of anti-estrogens in human urine for anti-doping
purposes. Several GC/MS screening procedures applied to
anti-estrogenic agents were developed [14–17], even if an
increasing number of procedures based on LC/MS have been
published [18–22]. Anti-estrogenic agents are often screened
together with other class of substances, mainly using LC-MS/
MS procedures, usually more sensitive than GC/MS ones.
Fast GC/MS is gaining importance in routine analytical
laboratories, since it improves sample throughput and global
productivity, as is necessary in laboratories where a consider-
able number of daily samples have to be processed [23,24]. The
time needed for instrumental determination can be drastically
shortened using short and narrow columns (5–10 m, i.d. 0.05–
0.1 mm), fast temperature ramping and high carrier gas ﬂow
rate as recently demonstrated [25–29].
Aim of the present work was to develop an analytical
procedure addressed to the fast screening of fourteen anti-
estrogenic drugs and metabolites (Fig. 1), using fast-GC
instrumentation hyphenated to electron ionization mass spec-
trometry. Further ‘‘in vitro’’ metabolic experiments using the
microsomal fraction from rat liver were carried out in order to
supply us the reference material for a larger panel of
metabolites. Lastly, urinary samples from patients under
treatment with anti-estrogenic drugs were collected andsuccessfully analyzed to test the actual efﬁciency of the
proposed method.2. Experimental
2.1. Chemicals and reagent
Methanol, t-butyl methyl ether (TBME) and various inorganic
salts were supplied by Riedel-de Hae¨n (Seelze, Germany);
b-glucuronidase (from Escherichia coli) and dithioerythritol
were from Sigma–Aldrich (Milan, Italy). N-Methyl–N-tri-
methylsilyltriﬂuoroacetamide (MSTFA) was obtained from
Macherey–Nagel (Du¨ren, Germany).
Aminoglutethimide, clomiphene citrate (57% cis form and
43% trans form), formestane and 17a-methyltestosterone were
purchased from Sigma–Aldrich (Milan, Italy); drostanolone
(17b-hydroxy-2a-methyl-5a-androstan-3-one), mesterolone (17b-
hydroxy-1a-methyl-5a-androstan-3-one) were from Steraloids
(Newport, RI, USA); drostanolone metabolite (3a-hydroxy-
2a-methyl-5a-androstan-17-one), mesterolone metabolites
(1a-methyl-5a-androstan-3a,17b-diol, 3a-hydroxy-1a-methyl-
5a-androstan-17-one) were from LGC Promochem (Milan,
Italy), testolactone was from US Pharmacopeia (Rockville,
MD, USA). Tamoxifen citrate was kindly supplied by SOL-
MAG (Garbagnate, Italy); letrozole was kindly provided from
Novartis Pharma (Basel, Switzerland) and anastrozole was
kindly supplied by AstraZeneca (London, UK).
Bis-4-cyanophenylmethanol (a letrozole metabolite), 4-
hydroxy-clomiphene (a clomiphene metabolite) and 4-
hydroxy-tamoxifen (a tamoxifen metabolite) were obtained
from ‘‘in vitro’’ phase I metabolism from rat liver microsomal
fraction [30–32]. All reagents were supplied by Sigma–Aldrich
(Milan, Italy).
Stock standard solutions were prepared in methanol at a
concentration of 1000 mg/mL and were stored at 20 1C until
used. All solution and buffers were prepared using deionized
water obtained from Milli-Q System (Millipore Corporate
Headquarters, Billerica, USA).
2.2. In vitro synthesis of phase I letrozole, clomiphene and
tamoxifen metabolites
2.2.1. In vitro metabolic assays
Liver microsomal fraction was prepared as described else-
where [31]. Stock solutions (500 mM) of each substrate tested
for in-vitro metabolic activity (letrozole, clomiphene and
tamoxifen) were prepared in DMSO. Reaction mixtures were
prepared in a test tube by adding 225 mL of 0.1 M Tris HCl
buffer (pH 7.4), 225 mL of a microsomal suspension (approxi-
mately 2 mg of proteins), 2000 mL of NADPH generating
system (consisting of 0.32 mM NADPH, 6.4 mM glucose-6-
phosphate, 0.5 U/mL glucose-6-phosphate dehydrogenase,
5 mM MgCl2 solution and 0.8 mM of EDTA solution) and
50 mL of 500 mM stock solution containing the tested sub-
strate. The reaction mixtures were incubated at 37 1C under
gentle agitation for 30 min and lastly the reaction was stopped
by cooling the mixture on ice. Metabolized substrate suspen-
sions were stored at 80 1C until used. The extraction of
metabolism products from the resulting suspensions was
carried out following the same procedure used for the urine
samples and described as follows.
Figure 1 Chemical structures of the anti-estrogenic agents considered in this study.
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The substrates obtained by ‘‘in vitro’’ metabolic assays were
characterized by GC/MS after solvent extraction and tri-
methylsilylation, as described in the subsequent paragraph.
GC/MS analyses were performed using an Agilent 6890N/
5975 instrument (Agilent Technologies, Milan, Italy) with a
17 m HP-1 fused silica capillary column (J&W Scientiﬁc), with
i.d. 0.20 mm and ﬁlm thickness 0.11 mm. The carrier gas was
helium (ﬂow rate 1 mL/min, split ratio 1:10). The oven
temperature program was: isothermal at 180 1C for 3 min,
heating rate of 5 1C/min up to 240 1C, then 10 1C/min to
270 1C, and lastly 40 1C/min to 320 1C (isothermal for 3 min).
The temperatures of transfer line, injection port and MS
detector were all set at 280 1C. Acquisition was carried out
in full scan mode from m/z 50 to m/z 550. The correct identity
of metabolites was determined by both mass spectral inter-
pretation and comparison with published spectra.2.4. Sample preparation
The sample preparation introduced minor modiﬁcations from
the standard operating procedure described by Donike et al. [33]
for the detection of anabolic steroids. Urine samples (3 mL) were
added with 15 mL of a 10 mg/mL methyltestosterone solution,
used as the internal standard (IS), and then were buffered to pH
7.4 with 2 mL of a 0.1 M phosphate buffer (prepared by
dissolving 4.63 g of KH2PO4 and 11.75 g of Na2HPO4  2 H2O
in 1 L of water). 30 mL of b-glucuronidase from E. coli were
subsequently added and the mixture was incubated at 55 1C for
1 h. Once the hydrolysis was completed, the mixtures were
cooled at room temperature and 2 mL of 0.1 M carbonate buffer
(prepared by dissolving 2.12 g of Na2CO3 and 6.72 g of NaHCO3
in 1 L of water) were added to raise the pH to 9.6. Liquid–liquid
extraction (LLE) was performed by adding 10 mL of TBME and
shaking in a multimixer for 10 min. After centrifugation at
2200 rpm for 3 min, the organic layer was transferred into a test
E. Gerace et al.4tube and dried under nitrogen at 70 1C. The dry residue was
derivatized with 50 mL of a MSTFA/NH4I/dithioerythritol
(1000:2:4, v/w/w) solution for 30 min at 70 1C. An aliquot of
1 mL was injected into the fast-GC/MS system.2.5. Fast-GC/MS analysis
Fast-GC/MS determinations were performed using a 6890N
GC, combined with a 5975 inert Mass Selective Detector
(Agilent Technologies, Milan, Italy), with electron ionization
at 70 eV. A 5 m fused-silica capillary column (Supelco ‘‘Equity
1’’), with i.d. 0.1 mm and ﬁlm thickness 0.11 mm was utilized
for GC separation. The ﬁnal analytical solution (1 mL) was
injected into the fast-GC system operating in the split mode
(5:1). Helium was employed as carrier gas at constant pressure
of 33.21 psi. The GC oven temperature was isothermally set
at 180 1C for 0.5 min, then initially raised to 220 1C with a
35 1C/min heating rate and subsequently to 310 1C with a rate
of 60 1C/min, followed by a isothermal period of 1 min at
310 1C. The total run time was 4.14 min, while the overall
cycle time, including oven cooling and thermal equilibration
was about 6 min. The GC injector and transfer line were
maintained at 280 1C. Data were acquired in the selected-ion
monitoring (SIM) mode at dwell time of 15 ms, using for each
compound detection the diagnostic ions listed in Table 1.2.6. Method validation
2.6.1. Selectivity
Ten different blank urine samples were deconjugated,
extracted, derivatized and analyzed as described above. The
occurrence of possible interferences from endogenous sub-
stances or derivatization byproducts was tested by monitoring
the selected-ion chromatograms, characteristic for eachTable 1 Molecular weights of the 14 analytes and their TMS-der
corresponding retention time windows used in SIM experiments.
Analytes Analyte
molecular
weight
No. of TMS
groups
TMS
molec
Anastrozole 294 0 294
Letrozole metabolitea 234 1 306
Aminoglutethimide 232 3 448
Aminoglutethimide 232 4 520
Drostanolone met (3a-ol-17-one) 304 2 448
Mesterolone met (3a-ol-17-one) 304 2 448
Mesterolone met (3a,17b-diol) 306 2 450
Tamoxifen 371 0 371
Mesterolone 304 2 448
Drostanolone 304 2 448
ISTD 302 2 446
Tamoxifen metabolitea 387 1 459
Testolactone 300 2 444
Formestane 302 3 518
Clomiphene (two isomers) 405 0 405
405 0 405
Clomiphene metabolitea 421 1 493
aReference material obtained by in vitro metabolism experiments.investigated compound, at the retention time interval expected
for their elution.
2.6.2. Linearity
The linear calibration model was checked by analyzing (three
replicates) negative urine samples spiked with standard solu-
tions at six concentration levels for each analyte. The linear
calibration parameters were obtained using the least squares
regression method, while the correlation coefﬁcients (R2) were
utilized to estimate linearity. Quantitative results from area
counts were corrected using the IS signal.
2.6.3. Limit of detection (LOD)
LOD values were estimated as the analyte concentrations
whose response provided a S/N value equal to 3, as deter-
mined from the least abundant among qualiﬁer ions. LOD
numerical values were extrapolated from S/N values at the
lowest concentration level (LCL) using the corresponding
calibration curve. The noise was measured from 0.05 min
before the peak onset till the beginning of the GC peak for
each analyte. Extrapolated LOD values were experimentally
conﬁrmed by studying urine samples spiked with all analytes
at LODs concentrations.
2.6.4. Extraction recovery
Extraction recoveries were calculated by comparing two
experimental sets of data. In the ﬁrst set, ten blank urine
samples were spiked before the extraction step with all
analytes at 50, 250 and 500 ng/mL ﬁnal concentration, except
for testolactone added at 250, 500 and 1000 ng/mL concentra-
tion. In the second set, ten blank urine samples were spiked
after the extraction step, with standard working solutions, at
the same ﬁnal concentration of 50, 250 and 500 (or 1000) ng/mL.
Recovery (%) was calculated as the ratio between theivatives, GC retention times, characteristic ions (EI mode) and
derivatives
ular weight
RT (min) Ions (m/z) EI RT time
window (min)
Target Others
1.90 209 293, 266 1.80–2.40
1.94 217 291, 190 1.80–2.40
2.14 291 276, 433 1.80–2.40
2.14 491 520, 505 1.80–2.40
2.44 433 448, 343 2.40–2.54
2.52 433 448, 343 2.40–2.54
2.56 345 450, 435 2.54–2.66
2.59 58 72, 371 2.54–2.66
2.59 141 157, 433 2.54–2.66
2.63 448 405, 141 2.54–2.66
2.74 446 301, 431 2.66–2.80
2.74 58 72, 459 2.66–2.80
2.75 444 429, 206 2.66–2.80
2.85 518 503, 147 2.80–2.88
2.92 86 100, 405 2.88–4.13
2.99 86 100, 405 2.88–4.13
3.33 86 100, 493 2.88–4.13
Rapid determination of anti-estrogens in urine by GC/MS 5response (peak area) obtained from the two separate series of
samples.
2.6.5. Repeatability (intra-assay precision)
Intra-assay precision (repeatability), expressed as percent
variation coefﬁcient (CV%), was assessed by extracting and
analyzing ten replicates of negative urine samples, spiked with
the standard solutions at two concentration levels (ﬁnal
concentrations of 50 ng/mL and 500 ng/mL for each analyte),
performed by the same operator. Standard criteria taken from
the literature [34] designate satisfactory intra-assay precision
for qualitative screening methods when CV% values are below
15% at 500 ng/mL concentrations and below 25% at 50 ng/mL
concentrations.
2.6.6. Robustness
The method robustness was evaluated by changing the
operators involved in both preparative and instrumental
phases of analysis, as well as the batch of chemicals and
reagents employed in the sample treatment and the spiking
level of several urine samples. For each analyte, compliance of
RT, relative ion abundances and approximate concentrations
were veriﬁed.
2.7. Real urine samples
Three urine samples from women suffering from breast
metastatic cancer and under treatment with Arimidexs (ana-
strozole), Femaras (letrozole) and Nolvadexs (tamoxifen
citrate) were collected and analyzed. Aliquots of 30 mL of
urine were collected and stored at20 1C until analysis. All
selected patients provided a fully informed permission for the
scientiﬁc use of these analyses.3. Results and discussion
3.1. GC/MS characterization of phase I letrozole, clomiphene
and tamoxifen metabolites
The derivatized extracts obtained from ‘‘in-vitro’’ metabolic
assays yielded relatively clean chromatographic proﬁles, from
which the identiﬁcation of the starting drugs and their phase I
metabolic products was straightforward. However, the experi-
mental mass spectra obtained from these metabolites were
compared with literature spectra, for a correct structural
identity assignment [15,35].
Fig. 2 shows the total-ion chromatograms, mass spectra
and fragmentation patterns for the derivatized metabolites
of letrozole (bis-4-cyanophenyl-methanol), clomiphene (4-
hydroxy-clomiphene) and tamoxifen (4-hydroxy-tamoxifen),
obtained from ‘‘in vitro’’ metabolic experiments.
The bis-4-cyanophenyl-methanol is the main inactive meta-
bolite of letrozole [15]. The mono-TMS derivative shows the
molecular ion at m/z 306 (relative abundance of 2%) and a
high-mass fragment m/z 291 (56%), due to the loss of a methyl
radical from the TMS residue. The fragment at m/z 217 (base
peak) is generated by the trimethylsiloxy-radical elimination,
while a subsequent rearrangement leads to the m/z 190 ion
(44%) by HCN loss.
Hydroxylation of the aromatic ring represents the main
phase I metabolic route for clomiphene [31]. The molecularion of main clomiphene metabolite, namely 4-hydroxy-clomi-
phene, is detected from its mono-TMS derivative at m/z 493
(2%); cleavage of the C–C bond in a-position to the amino
group leads to the fragment at m/z 86 (base peak), while
cleavage of the C–C bond in b-position to the amino group
yields the fragment at m/z 100 (8%).
Hydroxylation of the aromatic ring also occurs in the
tamoxifen metabolism, yielding 4-hydroxy-tamoxifen [36,37].
The major fragmentation of its mono-TMS derivative is
determined by the localization of the positive charge on the
amino-group, yielding both the base peak at m/z 58 (base
peak) and the major fragment at m/z 72 (39%) resulting from
the cleavage in a- and b-position with respect to the amino
group. The presence of the hydroxyl group on the tamoxifen
structure is testiﬁed by the metabolite molecular ion at m/z
459 (8%).
3.2. Derivatization products
Most anti-estrogenic agents and their metabolites listed in
Fig. 1 contain polar groups in their structures, that make them
non-volatile and unsuitable for gas chromatographic separa-
tion. Therefore, the development of an efﬁcient GC/MS
protocol, for identifying anti-estrogen in biological matrices,
requires preliminary derivatization of these polar groups.
Trimethylsilylation makes the analytes more volatile and
produces a molecular weight increase of 72 u, for each reactive
hydrogen. For steroids and anti-estrogenic agents such as
drostanolone and mesterolone containing more than one polar
group, MSTFA is proved to be the most efﬁcient agent to give
TMS ethers, since it produces single fully substituted deriva-
tives nearly without side-products, whose signiﬁcant mass
spectra contain diagnostic target ions, ideal for screening
purposes [15,16,25,35].
MSTFA reacts with all hydroxyl and keto groups of anti-
estrogenic agents, and amine and amide hydrogens of ami-
noglutethimide, to give their tris–TMS and tetrakis–TMS
derivatives, respectively. The absence of exchangeable hydro-
gens on anastrozole, clomiphene and tamoxifen does not
prevent their detection, as unmodiﬁed molecules. The mole-
cular weights of the original anti-estrogenic agents and their
derivatives, together with the number of TMS-groups intro-
duced by the derivatization, are reported in Table 1.
3.3. Fast GC/MS characterization
Full scan electron ionization mass spectra of all parent drugs
were recorded from reference standards, in order to determine
the most appropriate SIM protocol for accurate and sensitive
detection of these target analytes. Likewise, full scan mass
spectra for target metabolites were recorded from in vitro
metabolic mixtures.
A previous study [15] including GC/MS experiments on
letrozole reference standards found that the detection of this
compound is difﬁcult, due to its poor chromatographic
properties using a standard polysiloxane column. We encoun-
tered the same problem and decided to detect letrozole from
its main metabolite, namely bis-4-cyanophenylmethanol,
whose determination does not involve difﬁculties.
The relative abundances of three characteristic ions (quali-
ﬁer ions vs. target ion) along the GC peak were used for the
Figure 2 GC/MS-SIM chromatograms of the derivatized extracts obtained from ‘‘in-vitro’’ metabolic assays, mass spectra and proposed
fragmentations pattern of letrozole (A), clomiphene (B) and tamoxifen (C) metabolites.
E. Gerace et al.6
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the coincidence of its retention time with the expected one. All
target analytes were easily characterized by different frag-
ments. The SIM protocol developed proved efﬁcient in
discriminating the interferences.
Table 1 reports retention times and selected ions, used for
the identiﬁcation of anti-estrogenic agents or their trimethyl-
silyl derivatives in the EI mode.
Fig. 3 shows the fast-GC/MS chromatogram of a mixture
of analytes at the calibration level concentration of 250 ng/mL
obtained in the SIM mode. It is noteworthy that the entire
GC/MS run was completed in about 3 min. Two more minutes
were needed for oven cooling, temperature equilibration and
injection. Satisfactory chromatographic separation of all
target analytes was obtained including clomiphene isomers.
Even if a fast gradient was applied for the chromatographic
separation, the high MS-sampling rate, using a modern
benchtop quadrupole mass analyzer, guaranteed a minimum
of 10 points across the chromatographic peak without sig-
niﬁcant loss of information. The peaks were adequately
described allowing a good integration reproducibility, as
demonstrated by satisfactory CV% values reported in Table 2.
The SIM protocol described in Table 1 was used to build
the calibration graphs for all analytes.
3.4. Method validation
According to ISO 17025 requirements and ICH guidelines
[38], all validation parameters useful to evaluate the overall
performance of a qualitative analytical method were investi-
gated, including selectivity, linearity, limit of detection, recov-
ery, repeatability and robustness.
3.4.1. Selectivity
Ion-chromatograms from 10 negative urine samples showed
no interfering signals (i.e. S/N ratio minor than 3) at the
retention time where each analyte is expected to elute. This
demonstrated that the method is selective for all 14 anti-
estrogenic agents and free from positive interference from
urine components and column bleeding.Figure 3 Fast GC/MS-SIM chromatogram of a blank urine
sample fortiﬁed with all target compounds at the concentration of
250 ng/mL: (1) anastrozole, (2) aminoglutethimide, (3) drostano-
lone metabolite (3a-ol-17-one), (4) mesterolone metabolite (3a-ol-
17-one), (5) mesterolone metabolite (3a, 17bdiol), (6) mesterolone,
(7) tamoxifen, (8) drostanolone, (9) testolactone, (10) formestane,
(11) clomiphene (two isomers).3.4.2. Linearity and limit of detection
The range of concentration studied was planned according to the
approximate response factors obtained from the preliminary
experiments with standard solutions. All calibration curves
proved linear as demonstrated by correlation values comprised
between 0.990 and 0.999. Calibration curves are not available for
clomiphene, letrozole and tamoxifen metabolites because their
purity and exact concentration are not known with certainty. The
experimental data relative to calibration curves, limits of detection
and S/N values for all target analytes are reported in Table 3.
LOD values obtained for most target compound were found at
10 ng/mL, including the ones for formestane, tamoxifen, drosta-
nolone, mesterolone (and their metabolites), while few LOD
values (15–45 ng/mL) slightly exceeded this limit except the one
for testolactone that was 200 ng/mL.
A blank urine sample, spiked with the target analytes at the
LOD concentrations indicated in Table 3, was analyzed in
triplicate. All experimental S/N values observed exceeded the
critical value of 3, as expected.3.4.3. Extraction recovery
Extraction recoveries were calculated by comparing the results
from blank urine samples spiked before the extraction step
with the ones from negative urine samples, which were ﬁrst
extracted and then spiked, before the analysis. The results
obtained at 50 ng/mL concentration are reported in Table 2.
Most recovery values ranged from 102.7% (mesterolone) to
83.7% (mesterolone metabolite—3a,17b-diol), with the excep-
tion of testolactone and drostanolone metabolite (3a-ol-17-
one) showing average recovery efﬁciencies of 40.6% and
35.3%, respectively. For the latter, the limited extraction
recovery that we observed is reﬂected in literature data [34],
while no previous data are available for liquid–liquid testo-
lactone extraction efﬁciency. It should be noted that the
extraction recoveries were quite stable, even for the two
compounds with lower efﬁciency, as is demonstrated by
CV% values, all ranging between 10% and 18%. Taking into
account that a screening method for multiple target analytes is
not likely to provide homogeneously high extraction recov-
eries and that a 35% recovery is acceptable for a qualitative
screening, provided good extraction repeatability is obtained,
it can be concluded that the observed extraction efﬁciencies
are perfectly compatible with the screening purpose of the
present method. Extraction efﬁciency data obtained at higher
concentrations (250 and 500 ng/mL) conﬁrmed the results pre-
sented in Table 3, with a slight decrease of most recovery values.
For example, at the concentration of 500 ng/mL, recovery
efﬁciency values were comprised between 101.4% of formestane
and 72.9% of aminoglutethimide as tris-TMS derivatives.
Recovery value for drostanolone metabolite (3a-ol-17-one)
spiked at the highest concentration dropped to 20.3%, while
for testolactone no important difference with the result obtained
at lower concentration was observed (40.0%).3.4.4. Repeatability (intra-assay precision) and robustness
The identiﬁcation criteria, including the coincidence of reten-
tion times and the relative abundances of characteristic ions,
were respected all over the repeated tests. The repeatability
proved satisfactory for all the target analytes, as the coefﬁcient
of variation percentage (CV%) was always abundantly lower
than 25% for the samples spiked at 50 ng/mL, and lower than
Table 2 Percentage recovery (%) and repeatability (intra-assay precision) (CV%) for each analyte tested. The metabolites from
in-vitro assays are not included.
Detected analytes Extraction efﬁciency Repeatability
Conc. (ng/mL) Recovery (%) CV% CV% at
50 ng/mL
CV% at
500 ng/mL
Anastrozole 50 89.2 13.3 n/a 7.6
Aminoglutethimide (3TMS) 50 88.9 11.9 20.2 11.1
Aminoglutethimide (4TMS) 50 92.8 17.7 10.2 8.5
Drostanolone met (3a-ol-17-one) 50 35.3 17.8 13.8 12.0
Mesterolone met (3a-ol-17-one) 50 85.8 17.7 13.0 9.4
Mesterolone met (3a,17b-diol) 50 83.7 12.3 9.4 9.0
Tamoxifen 50 94.8 14.2 7.6 7.3
Mesterolone 50 102.7 17.0 12.2 9.1
Drostanolone 50 97.7 12.2 9.6 8.5
Testolactone 250 40.6 10.2 n/a 9.1
Formestane 50 97.9 11.5 9.2 8.6
Clomiphene (two isomers) 50 93.9 12.1 8.7 9.7
50 91.5 12.2 8.1 9.5
n/a: not available.
Table 3 Calibration intervals; gradients, intercepts and R2 values obtained for calibration curves; LOD and S/N at Lowest
Calibration Level (LCL) values for the TMS derivatives of the investigated 11 anti-estrogenic agents. The metabolites obtained
from in-vitro assays are not included.
Analytes Calibration level
concentration (ng/mL)
Slope Intercept R2 LOD (ng/mL) S/N at LCL
Anastrozole 100–1000 0.595 0.586 0.996 45 7.0
Aminoglutethimide (3TMS) 50–1000 0.173 0.0401 0.997 25 6.8
Aminoglutethimide (4TMS) 50–1000 0.0413 0.0179 0.990 35 4.7
Drostanolone met (3a-ol-17-one) 25–1000 0.344 0.123 0.994 10 8.7
Mesterolone met (3a-ol-17-one) 25–1000 0.485 0.122 0.997 10 7.4
Mesterolone met (3a,17b-diol) 25–1000 0.103 0.0725 0.997 10 9.0
Tamoxifen 25–1000 1.22 0.0466 0.999 10 7.5
Mesterolone 25–1000 1.64 0.246 0.999 10 7.5
Drostanolone 25–1000 0.622 0.221 0.998 10 8.2
Testolactone 250–1000 0.0046 0.0106 0.990 200 4.4
Formestane 25–1000 1.08 0.102 0.999 10 9.6
Clomiphene (two isomers) 25–1000 0.730 0.122 0.999 15 5.3
25–1000 0.123 0.112 0.999 15 5.2
E. Gerace et al.812% for the samples spiked at 500 ng/mL. The repeatability
for testolactone was obviously tested only at 500 ng/mL.
No signiﬁcant variation of retention times, relative ion
abundance or limits of detection were observed by changing
the operator, the instrument (same model), the chemical
batches, the stock standard solutions and the sample volume.
In all experiments, no statistically signiﬁcant variations of
detected concentrations were obtained (data not shown).3.5. Real urine samples
Real urine samples were collected during outpatient medical
examination, not allowing a strict control of the time elapsed
from the last drug administration. The patients were being
treated with tamoxifen, anastrozole and letrozole. All the
samples examined turned out positive for the administereddrug. Chromatograms obtained by fast-GC/MS analysis of
three real urine samples from patients under treatment with
different anti-estrogenic agents are reported in Fig. 4. In the
ﬁrst urine sample (Fig. 4A) the estimated concentration of
anastrozole was 98 ng/mL. GC plots in the ﬁrst column show
the superimposed proﬁles of the selected ions used for the
different drugs identiﬁcation. Comparison with the GC graphs
represented in the third column, and relative to the real samples,
provide clear evidence that the relative ion abundances are
perfectly reproduced throughout each GC peak proﬁle. The
selected-ion chromatograms reported in the central column
demonstrate that the method developed is selective and no
interfering signals are present in the GC proﬁles.
Thus, all target analytes examined (and/or their metabolites)
were positively detected in real urine samples from patients
under pharmacological treatment, showing that the presented
method can ﬁnd practical application for clinical purposes.
Figure 4 Selected-ion chromatograms of extracted urine samples obtained from patients treated with (A) anastrozole, (B) letrozole and
(C) tamoxifen. For letrozole and tamoxifen the metabolites, not the original drug, are detected. Left: urine spiked reference standard;
center: blank urine; right: real urine samples.
Rapid determination of anti-estrogens in urine by GC/MS 94. Conclusions
The continuous effort to increase the analytical throughput in
biomedical determinations and reduce the time needed for theinstrumental analysis received new impulse from the introduc-
tion of fast-gas chromatography. Although the analytical
methods based on liquid chromatography combined with
multiple stage mass spectrometry are gaining increasing
E. Gerace et al.10popularity with respect to GC/MS, just because they allow
more rapid determinations, the extensive application of fast-
GC/MS procedures is likely to hold back this trend, by
considering the large difference in price, the diffuse experience
existing in the GC-based analytical methods and the absence
of signal suppression/enhancement phenomena, occasionally
occurring in electrospray ionization when complex biological
matrices are analyzed by LC/MS.
Analytical methods have to respond to the requirements
established by the speciﬁc inquiry under way. While in anti-
doping screening analysis a common goal is to identify the largest
number of prohibited substances with the lowest number of
analytical methods, independently from their pharmacological
effects, epidemiology studies are frequently addressed to the
detection of a certain class of drugs. Such inquiries may take
advantage of analytical methods speciﬁcally designed for the class
of substances under investigation. For anti-estrogenic agents, an
epidemiologic study is possibly of interest, as these compounds
are daily employed for clinical purposes (mainly in the treatment
of breast cancer or masculine and feminine infertility) or illicitly
used by athletes in order to treat or prevent the side effects
associated with anabolic androgenic steroids abuse.
Fast-GC/MS analysis, performed on narrow bore columns at
high heating rates, provides signiﬁcant reduction of the time
required for the analysis of these anti-estrogenic agents, while
maintaining chromatographic separation, limits of detection, and
repeatability comparable with those obtained by conventional
GC. This makes the method particularly suited for routine
analysis, especially when a considerable number of samples have
to be analyzed, as about 10 injections/h could be performed.
The method proposed in the present study is selective for
the detection of anti-estrogenic agents in human urine. The
method appears to be sufﬁciently ﬂexible to include new
substances (and metabolites) of the same class that may
appear on the market in the future. Moreover, since fast-
GC/MS technique allows to lower the time needed for method
validation, a future extension of the present method on blood
samples could be rapidly performed.
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